Investors

Shield Therapeutics is well positioned to become a fast growing, independent, international specialty pharmaceutical company.

Why invest in Shield Therapeutics?

Shield has transformed from a development-focused, privately owned company into a PLC with increasingly commercially focused, customer-facing organisation set up to sell our innovative and value-added specialty pharmaceuticals that solve patients’ unmet medical needs.

£500m+

Annual Revenue

Targeted for Feraccru

£200m+

Annual Revenue

Targeted for PT20

£60m

Amount Raised

Since 2010